MEMS, Novo Nordisk and Roche launch ‘Changing Diabetes® in Children’ project in Malaysia to improve care for children and young adults below the age of 25 living with type 1 diabetes
Kuala Lumpur, 22 November 2023 – Novo Nordisk today announced a partnership with the Malaysian Endocrine and Metabolic Society (MEMS) and Roche Diagnostics Malaysia (Roche) to launch the Changing Diabetes® in Children (CDiC) project in Malaysia – a long-term initiative with a dedicated focus on improving the quality of care for children and young adults with type 1 diabetes. Children and young adults who have type 1 diabetes in Malaysia will receive free glucose monitoring supplies (glucometer and glucose test strips) – a significant advance in the management of diabetes in children and young adults. With its launch in Malaysia, CDiC will contribute to improving access to care, in line with this year’s World Diabetes Day theme of “Access to Diabetes Care”.
Type 1 diabetes is the most common form of childhood diabetes in Malaysia, accounting for 73%–77% of all childhood diabetes1, and the International Diabetes Federation reported 955 cases of type 1 diabetes in Malaysian children aged 0–19 years in 20212. Nationally, the misdiagnosis rate for children with type 1 diabetes is 38.7%3, which highlights the need for improving both awareness and access to care for childhood type 1 diabetes.
The CDiC project aims to bridge critical gaps in diagnosis, support in self-monitoring of blood glucose, and patient knowledge by building on existing efforts to address local barriers to healthcare, supporting the development of comprehensive diabetes care solutions and integrating with local healthcare systems. Specific components of CDiC in Malaysia include providing educational workshops for patients and their caregivers, training healthcare professionals in the diagnosis and management of the disease, establishing or refurbishing diabetes resource centres, developing a national registry, research on type 1 diabetes management, as well as raising public awareness of type 1 diabetes in Malaysia.
The partnership was launched today by Dato’ Dr. Mohd. Azman bin Yacob, Director of the Medical Development Division from the Ministry of Health Malaysia, and was attended by project partners, healthcare professionals in diabetes care, as well as patients with type 1 diabetes and their caregivers. In the event, attendees heard about the treatment landscape in Malaysia, current management of type 1 diabetes, as well as the patient journey and challenges from Dr. Nurain Mohd Noor, President of MEMS and the chair of the CDiC project in Malaysia; Mr. Anand Shetty, the Corporate Vice President, Business Area of South East Asia of Novo Nordisk; and Bryan Koh, Cluster Head of Asia Pacific Mature Markets, Roche Diabetes Care.
Dr. Nurain Mohd Noor, President of MEMS and the Chair of CDiC project Malaysia said, “The misdiagnosis rate of Malaysian children with type 1 diabetes is alarmingly high as children and young adults are often diagnosed with alternative conditions like respiratory or gastrointestinal illnesses. To address this pressing issue and ensure timely and accurate diagnoses and care, initiatives such as ‘Changing Diabetes® in Children’ are important for more timely interventions and improved care. The project will also equip frontliners with knowledge and management skills to help them help their patients with type 1 diabetes.”
Anand Shetty, the Corporate Vice President, Business Area South East Asia of Novo Nordisk stated, “Our purpose is to drive change to defeat chronic diseases such as diabetes by pioneering scientific breakthroughs and improving the lives of patients. With our CDiC partners in Malaysia, we aim to improve the lives of vulnerable type 1 diabetes patients by building a holistic system of care for children and young adults under the age of 25 living with type 1 diabetes.”
Bryan Koh, Cluster Head of Asia Pacific Mature Markets, Roche Diabetes Care, said, “We are committed to enhancing access to essential diabetes care for children and young adults living with type 1 diabetes in Malaysia with our partners, through building a sustainable continuum of care to support them in growing up well and fulfilling their full potential.”
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 59,000 people in 80 offices around the world, and market our products in 170 countries.
About Malaysian Endocrine and Metabolic Society
The Malaysian Endocrine and Metabolic Society (MEMS) is a professional medical body established in 1981 that aims to advance knowledge and practice in the field of endocrinology through promotion of research and organising post-graduate teaching courses as well as organising medical congresses.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 4,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care.
All trademarks used or mentioned in this release are protected by law
1. Fuziah MZ, Hong JYH, Zanariah H, Harun F, Chan SP, Rokiah P, et al.. A National Database on Children and Adolescent with Diabetes (e-DiCARE): Results from April 2006 to June 2007. Med J Malaysia (2008) 63(Suppl C):37–40.
2. International Diabetes Federation . IDF Diabetes Atlas, 10th. Brussels, Belgium: International Diabetes Federation; (2021)
3. Mavinkurve et al., 2021. Is Misdiagnosis of Type 1 Diabetes Mellitus in Malaysian Children a Common Phenomenon? Front Endocrinol (Lausanne). 2021; 12: 606018.